Author/Authors :
Okazaki، نويسنده , , Toshiyuki and Kageji، نويسنده , , Teruyoshi and Kuwayama، نويسنده , , Kazuyuki and Kitazato، نويسنده , , Keiko T. and Mure، نويسنده , , Hideo and Hara، نويسنده , , Keijiro and Morigaki، نويسنده , , Ryoma and Mizobuchi، نويسنده , , Yoshifumi and Matsuzaki، نويسنده , , Kazuhito and Nagahiro، نويسنده , , Shinji، نويسنده ,
Abstract :
Interferon-beta (IFN-β) is reported to augment anti-tumor effects by temozolomide in glioblastoma via down-regulation of MGMT. Promyelocytic leukemia (PML), a gene induced by IFN-β, is a tumor suppressor. Here, we report for the first time that in combination therapy, an IFN-β-induced increase in endogenous PML contributes to anti-tumor effects in p53 wild- and mutant glioma cells in a xenograft mice model. The increased PML promoted the accumulation of p73, a structural and functional homolog of p53, to fuse the coactivator Yes-associated-protein in the PML nuclear bodies. The adjuvant therapy targeted at PML may be a promising therapeutic strategy for glioblastoma.
Keywords :
Glioblastoma , apoptosis , PML , Yap , p73